271 related articles for article (PubMed ID: 34370076)
1. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
[TBL] [Abstract][Full Text] [Related]
2. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration.
Piscitelli J; Reddy MB; Wollenberg L; Del Frari L; Gong J; Wood L; Zhang Y; Matschke K; Williams JH
Clin Pharmacokinet; 2024 Apr; 63(4):483-496. PubMed ID: 38424308
[TBL] [Abstract][Full Text] [Related]
3. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
[TBL] [Abstract][Full Text] [Related]
4. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
[TBL] [Abstract][Full Text] [Related]
5. Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.
Csonka D; Bruderer S; Schultz A; Soergel M; Stepanova R; Sabattini G; Perez-Ruixo JJ
Clin Drug Investig; 2019 Dec; 39(12):1223-1232. PubMed ID: 31552642
[TBL] [Abstract][Full Text] [Related]
6. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
9. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
10. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
[TBL] [Abstract][Full Text] [Related]
12. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Mohamed MF; Coppola S; Feng T; Camp HS; Kim E; Othman AA
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1335-1344. PubMed ID: 34109764
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study.
Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K
Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.
Wu HF; Hristeva N; Chang J; Liang X; Li R; Frassetto L; Benet LZ
J Pharm Sci; 2017 Sep; 106(9):2751-2757. PubMed ID: 28385543
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
Jordy AB; Albayaty M; Breitschaft A; Anderson TW; Christiansen E; Houshmand-Øregaard A; Manigandan E; Bækdal TA
Clin Pharmacokinet; 2021 Sep; 60(9):1171-1185. PubMed ID: 33782832
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Wilson RH; Evans TJ; Middleton MR; Molife LR; Spicer J; Dieras V; Roxburgh P; Giordano H; Jaw-Tsai S; Goble S; Plummer R
Br J Cancer; 2017 Mar; 116(7):884-892. PubMed ID: 28222073
[TBL] [Abstract][Full Text] [Related]
19. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
[TBL] [Abstract][Full Text] [Related]
20. Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects.
Maekawa Y; Furuie H; Kato M; Myobatake Y; Kamiyama E; Watanabe A; Shiosakai K; Taguchi T; Bass R; Zhou J; Dishy V; Warren V; Vashi V; Ishizuka H
Clin Drug Investig; 2019 Oct; 39(10):967-978. PubMed ID: 31321631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
